ADMA Biologics (NASDAQ:ADMA) Upgraded to Hold at Zacks Research

ADMA Biologics (NASDAQ:ADMA) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday, Zacks reports.

Other analysts also recently issued research reports about the stock. Canaccord Genuity Group dropped their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Mizuho dropped their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Finally, Raymond James Financial began coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price on the stock. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

ADMA Biologics Price Performance

ADMA stock opened at $9.58 on Wednesday. The stock has a 50-day moving average price of $9.13 and a two-hundred day moving average price of $10.31. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $20.46. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The company has a market cap of $2.15 billion, a PE ratio of 13.69 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. The company had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The firm’s revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.14 earnings per share. As a group, research analysts predict that ADMA Biologics will post 0.78 EPS for the current year.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently made changes to their positions in ADMA. Summit Securities Group LLC acquired a new stake in ADMA Biologics during the fourth quarter worth about $29,000. Western Wealth Management LLC acquired a new position in shares of ADMA Biologics during the 1st quarter valued at $31,000. iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics in the third quarter valued at $34,000. EverSource Wealth Advisors LLC lifted its holdings in ADMA Biologics by 385.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,180 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in ADMA Biologics during the second quarter valued at approximately $51,000. 75.68% of the stock is owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.